BRIEF RESEARCH REPORT article

Front. Cell. Infect. Microbiol., 19 October 2022

Sec. Clinical and Diagnostic Microbiology and Immunology

Volume 12 - 2022 | https://doi.org/10.3389/fcimb.2022.955481

NGS in the clinical microbiology settings

    MP

    Milena Pitashny 1,2*

    BK

    Balqees Kadry 1

    RS

    Raya Shalaginov 2

    LG

    Liat Gazit 2

    YZ

    Yaniv Zohar 3

    MS

    Moran Szwarcwort 2

    YS

    Yoav Stabholz 4

    MP

    Mical Paul 4

  • 1. Clinical and Research Microbiome Center, Research Division, Rambam Health Care Campus, Haifa, Israel

  • 2. Clinical Microbiology Laboratories, Laboratories Division, Rambam Health Care Campus, Haifa, Israel

  • 3. Pathology Institute, Rambam Health Care Campus, Haifa, Israel

  • 4. Infectious Diseases Unit, Rambam Health Care Campus, Haifa, Israel

Article metrics

View details

10

Citations

5,7k

Views

2,1k

Downloads

Abstract

We hypothesized that targeted NGS sequencing might have an advantage over Sanger sequencing, especially in polymicrobial infections. The study included 55 specimens from 51 patients. We compared targeted NGS to Sanger sequencing in clinical samples submitted for Sanger sequencing. The overall concordance rate was 58% (32/55) for NGS vs. Sanger. NGS identified 9 polymicrobial and 2 monomicrobial infections among 19 Sanger-negative samples and 8 polymicrobial infections in 11 samples where a 16S gene was identified by gel electrophoresis, but could not be mapped to an identified pathogen by Sanger. We estimated that NGS could have contributed to patient management in 6/18 evaluated patients and thus has an advantage over Sanger sequencing in certain polymicrobial infections.

Introduction

Most clinical infections are not microbiologically confirmed. The problem is especially pertinent in deep seated invasive infections, where microbiological diagnosis is critical and the specimen is precious, such as osteomyelitis, deep organ abscesses, brain empyema or others. For these cases, there has been a growing interest and implementation of broad-range polymerase chain reaction (PCR) based Sanger sequencing of the 16S ribosomal RNA (rRNA) bacterial gene (panbacterial PCR), directly from clinical specimens (Rampini et al., 2011). Sanger sequencing significantly improved the diagnostic yield in clinical culture isolates as well as mono-microbial infections (Shachor-Meyouhas et al., 2013; Khoury et al., 2019). However, when more than one species are present in the specimen, Sanger sequencing template reads are superimposed and are generally uninterpretable (Salipante et al., 2013). Results from such specimens are reported as negative or as a mixture of bacteria, without further identification.

As in other fields of medicine, next generation sequencing (NGS) technologies have expanded diagnostic capabilities in clinical microbiology laboratories. Recent studies have highlighted the ability of 16S rRNA NGS to accurately reach speciation and quantify bacterial abundances in complex polymicrobial infections (Salipante et al., 2013; Abayasekara et al., 2017; Culbreath et al., 2019).

We hypothesized that for difficult-to-diagnose infections, especially when polymicrobial, targeted NGS of the 16S rRNA gene has better diagnostic performance than panbacterial Sanger sequencing.

Materials and methods

We used residual nucleic acids from clinical specimens that were submitted to our reference molecular laboratory at RHCC for panbacterial, panfungal or mycobacterial PCR (Sanger sequencing). Samples were collected between 2020-2021 at Rambam Health Care Campus (RHCC) or other hospitals. DNA stored at -20oC was retrieved and tested by NGS retrospectively. Clinical information was available only for samples sent from within RHCC.

Broad-range 16S rRNA gene Sanger sequencing was performed using in-house protocols at the molecular bacteriology laboratory (Shachor-Meyouhas et al., 2013).

NGS library preparation and analyses were performed blinded to clinical information, culture or Sanger sequencing results. DNA extraction of bacterial DNA from each specimen was carried out using the QIAAmp® DNA Mini kit (QiagenGroup) according to manufacturer’s instructions. Each batch of specimens were extracted with negative controls (extraction control). PCR amplification of the hypervariable region V4 of the 16s rRNA gene was conducted using PCRBIO HS Taq Mix Red according to the Earth Microbiome Project primer pairs (Apprill et al., 2015; Parada et al., 2016), and in selected cases, the addition of V1-2 segments (F27-R338) of the same gene to better identify certain bacteria and improve speciation (such as for Staphylococcus and Enterobacterales) (Walker et al., 2015). PCR products were run on a 1.5% agarose gel. Final library products were purified using Qiaquick PCR Purification Kit (Qiagen Groups) according to manufacturer’s instructions and quantified using Qubit™ dsDNA HS and BR Assay Kits (Invitrogen).

We sequenced the amplified V1-2 or V4 regions of 16s rRNA gene with Ion S5â„¢ System (Thermo Fisher Scientific). Data were analyzed using the Ion Reporter bioinformatics Software pipeline (Thermo Fisher Scientific), using a threshold of 1000 mapped reads for designating significant pathogens. BAM files uploaded to the Ion Reporter were mapped to the Silva 138 SSU database. Typical contaminants found in negative controls, such as Acinetobacter lwofii, Acinetobacter schendleri, or Xanthomonadaceae which are water tolerant bacteria, were subtracted from overall reads obtained on the clinical samples.

Concordance between Sanger sequencing and NGS results was evaluated. For the RHCC samples, we estimated the potential clinical added value of NGS, had it been available in real time. Two physicians (infectious diseases and clinical microbiologist) evaluated each case and assigned the potential contribution of NGS to patient management independently (diagnosis and treatment). Disagreements were resolved by consensus.

The study was approved by the local ethics committee with a waiver of informed consent. NGS results were not conveyed to clinicians.

Results

The study included 55 specimens from 51 patients; 22 specimens from RHCC and all others from other hospitals. Of the 55 specimens evaluated, 25 specimens were Sanger positive with one organism reported. Of those, 24 were concordant by NGS (24/25) that identified the exact Sanger pathogen alone (N=12) or with additional pathogen/s (N=12). The only discordant result was a Propionibacterium spp identified by Sanger, that was missed by NGS. Sanger was negative in 19 samples, of which 8 were negative by NGS, 9 polymicrobial and 2 monomicrobial by NGS. In 11 samples, broad-range 16S gene was identified by gel electrophoresis, but could not be mapped to an identified pathogen within available databases when sequenced by Sanger technology (possible polymicrobial infection); among these, 3/11 were negative on NGS and all others were positive with polymicrobial identification (Figure 1 and Table 1).

Figure 1

Figure 1

Concordance between Sanger sequencing and NGS in a scheme. Sanger negative are those samples that did not give any signal on PCR gels. "Sanger unidentified" are those samples that presented a band in agarose gels, but on Sanger sequencing it was not possible to define a unique organism against public databases.

Table 1

Sample IDMaterialSanger resultsNGS resultsTotal number of mapped reads
Concordant, positive N=24 
NGS-1Tissue/skin/soft tissuePseudomonas aeruginosaPseudomonas spp 28% (Pseudomonas aeruginosa 2%)7946
NGS-14PusPseudomonas aeruginosaPseudomonas 74% (P.aeruginosa 39%)18412
NGS-15PusFusobacterium necrophorumFusobacterium necrophorum 34%16616
NGS-2WoundMycobacterium marinumMycobacterium spp 20%
V1-2:
Mycobacterium marinum
4208
NGS-20TissueStaphylococcus aureusStaphylococcus spp 71%(S. epidermidis11%, S. aureus 3%)
V1-2:
S.aureus 37%
9765
NGS-3TissueStreptococcus pyogenesStreptococcus pyogenes27%4929
NGS-33BloodSneathia sanguinegensSneathia sanguinegens 60%201717
NGS-39TissueStaphylococcus aureusStaphylococcus spp 72% (S. epidermidis 9% , S.aureus (1.5%))
V1-2:
S.aureus 63% (low counts 446)
2609
NGS-40lymph nodeStreptococcus pyogenesStreptococcus pyogenes 35%1440
NGS-46Pleural FluidEnterococcus sppEnterococcus spp 29% (E. moraviensis 1%)1569
NGS-7TissueStreptococcus dysgalactiae spp equisimilisStreptococcus dysgalactiae 30%13866
NGS-9TissueStaphylococcus aureusStaphylococcus spp 41% (S. epidermidis 4% )
V1-2:
Staphylococcus aureus 33%
2107
NGS-32SwabStreptococcus sanguisPolymicrobial (Rothia mucilaginosa 10%, Velionella dispar 12%, Prevotella 11% (P. histicola 5%, P.salivae 3%, others <1%) Streptococcus 35%, (S. australis 11%, S. infantis 3%, S thermophilus1%), Actinobacillus parahemolyticus 2%)2038
NGS-36BALStreptococcus mitisPolymicrobial (Rothia mucilaginosa 28%, Streptococcus 46% (S. australis 6%, S. infantis 8%), Velionella <1%)
V1-2:
(Streptococcus pneumonia 2% and Pseudomonas aeruginosa 3% in low counts 1059)
4870
NGS-53SwabHaemophilus influenzaeHaemophilus 35% (H. influenzae 20%), Peptostreptococcus anaerobius 2%1737
NGS-11FluidPorphyromonas sppPolymicrobial (Porphyromonas endodontalis 25%), Bacteroides fragilis 5%)10198
NGS-12PusEnterobacteriaceaePolymicrobial (Enterobacter 3%, Klebsiella 2% , Enterococcus 3% )20144
NGS-25Bronchial washPseudomonas sppPolymicrobial (Prevotella 15% (P. histicola11%, P.melaninogenica3%, P.veroralis <1%), Velionella dispar 7%, Pseudomonas spp 16%, Streptococcus spp 23 (S.infantis 1%anginosus, australis, thermophilus <1%) (V4)
V1-2:
Streptococcus 7% S. salivarius, S.mitis
54561
NGS-44AbscessEnterobacteriaceaeSalmonella 5%, Escherichia 2%699
NGS-49TissueProteus sppPolymicrobial (Peptoniphilus 23%, Finegoldia magna 1%)
V1-2:
Proteus mirabilis 40%, Enterococcus faecalis 4%, Morganella morganii 17%
889
NGS-50TissueFinegoldia sppPolymicrobial (Peptoniphilus 9%, Finegoldia magna 23%, Prevotella timonensis 10%, Anaeroccocus murdochii 5%)1614
NGS-51SwabCapnocytophaga sppPolymicrobial (Granulicatella adiacens 1%, Capnocytophaga leadbetteri 8% , Fusobacterium periodonticum<1%, Rothia mucilaginosa 4%, Neisseria cinerea15%, Haemophilus parainfluenzae 8%, Prevotella nanceiensis 3%, Streptococcus australis , Streptococcus infantis , Veillonella)7495
NGS-6PusMorganella sppPolymicrobial (Pseudomonas spp 39% (Pseudomonas aeruginosa 16%)
V1-2:
Morganella morgani 25%
4772
NGS-8PusPrevotella sppPolymicrobial (Prevotella melaninogenica 19%, Finegoldia magna 10%,Vellionella spp 10%, Gemella spp 4%)18344
Concordant, negative (N=8)
NGS-18TissueNegativeNegative551
NGS-21Synovial FluidNegativeNegative46968
NGS-22Synovial FluidNegativeNegative29735
NGS-24Tissue biopsy, abscessNegativeNegative0
NGS-29CSF, surgical siteNegativeNegative428
NGS-35CSFNegativeNegative494
NGS-43FluidNegativeNegative900
NGS-52CSFNegativeNegative1211
Discordant, Sanger-negative, N=11
NGS-13TissueNegativePolymicrobial (Streptococcus 20% S. infantis 1%, S. australis 1%, Granulicatella elegans 2%, Gemella spp 4%, Haemophilus parainfluenza 3%, Neisseria 1%, Rothia mucilaginosa 2%, Prevotella melaninogenica 6%)
V1-2: Helicobacter pylori 19%
7668
NGS-16Synovial fluidNegativePolymicrobial (Porphyromonas uenonis 3%, Prevotella oris 6%, Prevoltella oralis 2%, Parvimonas micra 5%, Eubacterium infirmum 3%, Fusobacterium 5%)9467
NGS-17Pleural fluidNegativePolymicrobial (Prevotella oris 1%, Parvimonas micra 1%, Fusobacterium 3%)2253
NGS-19TissueNegativePolymicrobial (Porphyromonas uenonis 1%, Parvimonas micra 2%, Fusobacterium 2%, Prevotella 2% oris and oralis)4612
NGS-23AbscessNegativeStaphylococcus 20% (S.aureus <1%, S. epidermidis 4%)
V1-2:
Staphylococcus aureus 20%
32376
NGS-26CSFNegativePolymicrobial (Staphylococcus 21% ( S. epidermidis 2%), Micrococcus 2%, Paenibacillus 5%, Legionella pneumophila 1.6%)
V1-2:
Legionella pneumophila 22%
3753
NGS-27Tissue-brainNegativeStaphylococcus 22% ( S. epidermidis 2%)3482
NGS-28TissueNegativePolymicrobial (Corynebacterium spp 10%, Dermatobacter hominis 2%, Anaerococcus murdochii 2%, Peptoniphilus 9%, Clostridium ramosum <1%)8514
NGS-30Tissue biopsyNegativePolymicrobial (Corynebacterium kroppenstedtii <1%, Enterobacteriaceae 5% (Enterobacter cloacae <1%))5123
NGS-4Wound swabNegativePolymicrobial (Prevotella oralis 1%, Prevotella oris 3%. Parvimonas micra 3%, Fusobacterium 9% (F. nucleatum <1%), Pseudomonas 2% (P.auruginosa <1%, P.hibiscicola <1%)8376
NGS-55BALNegativeStreptococcus 40% (S. infantis 5%)
V1-2 (very low counts 191):
Haemophilus parainfluenza
1175
Discordant, Sanger-positive, N=1
NGS-42Surgical wound/abscessPropionibacterium sppNegative504
Sanger positive but unidentified (N=11)
NGS-31PusPositive, unidentifiedNegative817
NGS-38BALPositive, unidentifiedNegative458
NGS-45BALPositive, unidentifiedNegative551
NGS-10TissuePositive, unidentifiedPolymicrobial (Finegoldia magna 18%, Enterococcus 11%, Bacteroides 21% ( B. ovatus 7, uniformis 5%), Parabacteroides 8% ( P. diastasonis4%), Corynebacterium 1% (C. jeikeium & tuberculostearicum <1%)11542
NGS-34Synovial fluid/ bone/ tissuePositive, unidentifiedPolymicrobial (V4 negative-only contaminants.
V1-2 (3890):
E.coli 1%, Brebundimonas nasdae 2%, Microbacterium chocolatum 2%, Acinetobacter hemolyticus 1%)
12452
NGS-37Urethral secretionPositive, unidentifiedPolymicrobial (Ureaplasma 27%, Corynebacterium tuberculostearicum 6%, Haemophilus Aegyptus 3%, Haemophilus influenza 3% , Staphylococcus 3%, Streptococcus 18% (S. infantis 3%))
V1-2:
Ureaplasma urealyticum 30%
7502
NGS-41BALPositive, unidentifiedPseudomonas 42% (P. auruginosa 14%), Streptococcus 44% (S. infantis 4%)3731
NGS-47BALPositive, unidentifiedPrevotella 33% (P.nanceiensis 16%)1296
NGS-48TissuePositive, unidentifiedPolymicrobial (Corynebacterium 7%, Campylobacter ureolyticus 7%, Anaerococcus vaginalis 6%, Finegoldia magna 10%, Peptoniphilus2%, Peptoniphilus 2%, Prevotella corporis7%, Streptococcus infantis <1% , Haemophilus 5% (H. aegyptius 3%, H. influenza 2%)
V1-2 (2121):
Moraxella catarrhalis 6%
8234
NGS-5TissuePositive, unidentifiedPolymicrobial (Pseudomonas spp 31% (P. aeruginosa 13%) Enterobacteriaceae 10% (Salmonella enterica 2.5%))2756
NGS-54BALPositive, unidentifiedStreptococcus 38% (S. infanti 5%)1318

Comparison between Sanger and NGS results.

Each specimen sent to the Clinical Microbiology Laboratory at Rambam for Sanger sequencing, was later sequenced with Ion torrent S5 for the amplification of the V4 hypervariable region of 16s ribosomal gene. Unless noted in the NGS results column, all sequences were found with the primer set V4. Whenever the addition of the variable region V1-2 gave further characterization, it was noted in this table. In the last column , the number of mapped reads with V4. In the NGS results column, the percentage of those reads attributed to each organism.

Among the 22 RHCC specimens for which clinical information was available (18 patients), eight could have benefited from NGS for diagnosis (Figure 2 and Table 2): 4 polymicrobial (NGS-26, 30, 32, 34), 3 monomicrobial findings (NGS-23, 27, 54) and 1 genus identification of E.coli/Salmonella spp. in specimen NGS-44. We estimated that 6/18 patients would have benefited from antibiotic adjustment following NGS results and they all belong to the discordant group (Figure 2 and Table 2), while the other 12 patients would have been treated properly without any change in empiric treatment.

Figure 2

Figure 2

Effect of NGS findings on patient management. In 8/22 samples the result obtained with NGS contributed to diagnosis (also congruent when there were repeated samples from the same patient). In 6/18 patients, treatment could have been changed to a more appropriate one had NGS results been available at the time of diagnosis.

Table 2

Sample IDDiagnosisSangerNGS resultsWould have affected diagnosis?Antimicrobial treatmentWould have changed treatment?
Discordant 
NGS-30 Chronic internal fixation-associated infectionNegativePolymicrobial (Corynebacterium  kroppenstedtii, Enterobacteriaceae, Enterobacter cloacae)YesCefazolin+
Ciprofloxacin
Possibly
NGS-34Postpartum sacroiliac joint arthritisPositive, unidentifiedPolymicrobial (E.coli, Brebundimonas nasdae, Microbacterium chocolatum, Acinetobacter hemolyticus)Yes
(See NGS-33)
Piperacillin-Tazobactam, subsq: Metronidazole and then AmoxicillinYes
NGS-32Necrotizing cervical lymph node (HIV positive)Streptococcus sanguisPolymicrobial (Rothia mucilaginosa, Velionella dispar, Prevotella histicola, Prevotella salivae, Streptococcus australis, Streptococcus infantis, Actinobacillus parahemolyticus, Haemophilus parahemolyticus)Yes
(See NGS-31)
Unknown (No EMR access)Possibly
NGS-26Nosocomial meningitisNegativePolymicrobial (Legionella pneumophila, Staphylococcus epidermidis)YesMeropenem+
Vancomycin
Possibly
NGS-27Nosocomial meningitisNegativeStaphylococcus epidermidisYes
(See NGS-26)
Meropenem+
Vancomycin
Possibly
NGS-23 Chronic osteomyelitis with Leg abscessNegativeStaphylococcus aureusYesCefazolinNo
NGS-54Cavitary pneumonia (congenital neutropenia)Positive, unidentifiedStreptococcus salivariusYes
(See NGS-25)
MeropenemPossibly
NGS-44Arm fluctuant lesion (AML)EnterobacteriaceaeSalmonella, EscherichiaYesAmoxicillin-clavulanatePossibly
NGS-25Cavitary pneumonia (congenital neutropenia)Pseudomonas sppPolymicrobial (Streptococcus salivarius, mitis, anginosus, Prevotella melaninogenica, Velionella dispar , Pseudomonas aeruginosa)No. Positive culturePiperacillin-Tazobactam
Subsq.
Levofloxacin
No
NGS-41Hilar lymphadenopathy (AML)Positive, unidentifiedPseudomonas aeruginosaNo. Positive cultureLevofloxacinNo
NGS-4Jaw lesion (AML)NegativePolymicrobial (Prevotella oralis, Prevotella oris, Parvimonas micra, Fusobacterium nucleatum,  Pseudomonas aeruginosa, P.hibiscicola)No. MucormycosisAmphotericin-B + PosaconazoleNo
Concordant 
NGS-1Leg ulcerPseudomonas aeruginosaPseudomonas aeruginosaNoNo
NGS-2Left hand abscessMycobacterium marinumMycobacterium marinumNoNo
NGS-3Leg cellulitisStreptococcus pyogenesStreptococcus pyogenesNoNo
NGS-33Postpartum sacroiliac joint arthritisSneathia sanguinegensSneathia sanguinegensNoNo
NGS-21Suspected septic arthritis of hipNegativeNegativeNoNo
NGS-24SynovitisNegativeNegativeNoNo
NGS-29Nosocomial MeningitisNegativeNegativeNoNo
NGS-31Necrotizing cervical lymph node (HIV positive)Positive, unidentifiedNegativeNoNo
NGS-35Suspected Brain abscess and meningitisNegativeNegativeNoNo
NGS-42Deep neurosurgical site infectionPropionibacterium sppNegativeNoNo

Potential added value of NGS over Sanger for patient management.

Available clinical data was collected for samples sent from within Rambam. Retrospectively, a Clinical Microbiologist and an Infectious diseases specialist independently evaluated the diagnostic potential of NGS over Sanger and the potential for therapeutic modifications. Incongruences in the conclusions were solved by the two specialists by consensus.

In this study we describe the comparison between broad range Sanger panbacterial sequencing and targeted deep sequencing (NGS) on clinical samples submitted for panbacterial PCR. Overall, the concordance rate was 58% (32/55) for NGS vs. Sanger. Concordance was more frequent in Sanger-positive samples 24/25 (96%) than for Sanger-negative 8/19 (42%). Among five discordant Sanger-negative results with clinical information (Table 2), the positive NGS result would have been considered clinically-significant and might have improved diagnosis and/or management. In addition, NGS was able to identify possible pathogens in 8/11 Sanger-positive but pathogen-unidentified specimens. These results in a diagnostic advantage to targeted NGS. Moreover, polymicrobial communities identified by NGS may point to particular infection processes that may contribute to patients’ evaluation and optimal management. This is consistent with previous studies that validated the use of NGS for pathogen detection (Culbreath et al., 2019) and compared NGS to culture-based diagnosis (Abayasekara et al., 2017).

Discussion

The targeted NGS in-house assay was performed on the Ion torrent S5 instrument, used for microbiome purposes, with a predefined threshold of > 1000 mapped reads. The presence of certain pathogens, however, should always be considered as a potential cause of infection, even if the number of reads is below predefined cutoffs, in polymicrobial or monomicrobial results. Such is the case in specimens NGS-44 (699 mapped reads) where Salmonella identified by NGS was considered clinically -significant, and NGS-49 (889 reads) where Proteus mirabilis magna among other intestinal pathogens might have been clinically-significant. Conversely, the presence of common commensals should be interpreted carefully. The clinician and the clinical microbiologist must work together to attribute clinical significance to the NGS results.

NGS technology allows for the parallel coverage of all taxa present in a clinical specimen, resulting in the identification of complex microbial communities. The polymicrobial findings in our study likely represented polymicrobial infections. However, alternative explanations should be considered, such as the possibility of commensal microbiota present in non-sterile or sterile body sites, a non-sterile specimen collection technique, or contamination during laboratory workflows. To overcome the latter, species found in negative controls were considered contaminants in our study and their sequences were subtracted from results. During specimen collection and transportation, polymicrobial communities may change in composition. Sanger identifies the best amplified organism which is not necessarily representative of the dominant or pathogenic one

One central limitation of this study is that only bacterial organisms were targeted (V4 and V1-2 regions of 16S rRNA gene). In addition, samples were selected randomly for this analysis, but not consecutively. The study was non-interventional – NGS results were not used in clinical practice, thus its true effect on patient management remain unknown. One advantage of this study is that NGS was performed blinded to other microbiological and clinical information.

In conclusion, in this validation study we demonstrated superior pathogen identification with targeted 16s NGS compared to Sanger sequencing in clinical samples. We propose to consider NGS upfront in cases where polymicrobial infections are suspected. Further developments of NGS should include the addition of other important targets such as viral targets or Internal Transcribed Space (ITS) for fungi, as well as antimicrobial resistance genes. To better characterize the accuracy of results, comparison with shotgun metagenomics is necessary.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Statements

Data availability statement

The original contributions presented in the study are publicly available. This data can be found here: [DOI: 10.5281/zenodo.7119981].

Ethics statement

The studies involving human participants were reviewed and approved by Helsinki committee at Rambam HCC, Israel. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

Author contributions

Authors’ contributions: All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by MPi, BK, and YS. The first draft of the manuscript was written by MPi and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

  • 1

    AbayasekaraL. M.PereraJ.ChandrasekharanV.GnanamV. S.UdunuwaraN. A.LiyanageD. S.et al. (2017). Detection of bacterial pathogens from clinical specimens using conventional microbial culture and 16S metagenomics: a comparative study. BMC Infect. Dis.17 (1), 631.

  • 2

    ApprillA.McnallyS.ParsonsR.WeberL. (2015). Minor revision to V4 region SSU rRNA 806R gene primer greatly increases detection of SAR11 bacterioplankton. Aquat Microb. Ecol.75 (2), 129–137.

  • 3

    CulbreathK.MelansonS.GaleJ.BakerJ.LiF.SaeboO.et al. (2019). Validation and retrospective clinical evaluation of a quantitative 16S rRNA gene metagenomic sequencing assay for bacterial pathogen detection in body fluids. J. Mol. Diagn.21 (5), 913–923.

  • 4

    KhouryN.AmitS.GeffenY.AdlerA. (2019). Clinical utility of pan-microbial PCR assays in the routine diagnosis of infectious diseases. Diagn. Microbiol. Infect. Dis.93 (3), 232–237.

  • 5

    ParadaA. E.NeedhamD. M.FuhrmanJ. A. (2016). Every base matters: assessing small subunit rRNA primers for marine microbiomes with mock communities, time series and global field samples. Environ. Microbiol.18 (5), 1403–1414. doi: 10.1111/1462-2920.13023

  • 6

    RampiniS. K.BloembergG. V.KellerP. M.BüchlerA. C.DollenmaierG.SpeckR. F.et al. (2011). Broad-range 16S rRNA gene polymerase chain reaction for diagnosis of culture-negative bacterial infections. Clin. Infect. Dis.53 (12), 1245–1251.

  • 7

    SalipanteS. J.SenguptaD. J.RosenthalC.CostaG.SpanglerJ.SimsE. H.et al. (2013). Rapid 16S rRNA next-generation sequencing of polymicrobial clinical samples for diagnosis of complex bacterial infections. PloS One8 (5), e65226.

  • 8

    Shachor-MeyouhasY.SprecherH.MoscovizD.ZaidmanI.HaimiM.KassisI. (2013). Molecular-based diagnosis of bacteremia in the setting of fever with or without neutropenia in pediatric hematology-oncology patients. J. Pediatr. Hematol. Oncol.35 (7), 500–503.

  • 9

    WalkerA. W.MartinJ. C.ScottP.ParkhillJ.FlintH. J.ScottK. P. (2015). 16S rRNA gene-based profiling of the human infant gut microbiota is strongly influenced by sample processing and PCR primer choice. Microbiome3 (1), 1–11. doi: 10.1186/s40168-015-0087-4

Summary

Keywords

NGS, 16s, clinical microbiology, next generation sequencing, polymicrobial infections, polymicrobial

Citation

Pitashny M, Kadry B, Shalaginov R, Gazit L, Zohar Y, Szwarcwort M, Stabholz Y and Paul M (2022) NGS in the clinical microbiology settings. Front. Cell. Infect. Microbiol. 12:955481. doi: 10.3389/fcimb.2022.955481

Received

28 May 2022

Accepted

26 August 2022

Published

19 October 2022

Volume

12 - 2022

Edited by

Xin Zhou, Stanford University, United States

Reviewed by

Jiyuan Hu, New York University, United States; Tuhin Kumar Guha, Stanford University, United States

Updates

Copyright

*Correspondence: Milena Pitashny,

This article was submitted to Clinical Microbiology, a section of the journal Frontiers in Cellular and Infection Microbiology

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics